Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022. The expanded agreement gives AbbVie access to AbCellera's TCE platform for developing therapeutic antibodies targeting tumors.
Under the agreement terms, AbCellera will lead discovery activities while AbbVie retains development and commercialization rights for resulting therapeutic antibodies. AbCellera will receive upfront and research payments, plus potential downstream milestone payments and tiered royalties on net sales.
AbCellera (ABCL) has announced its participation in two major upcoming investor conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024, at 11:30 a.m. PT, and at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025, at 4:30 p.m. PT.
Both presentations will be accessible via live audio webcasts through links on AbCellera's Investor Relations website, with replay options available after the events.
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 39th Annual Meeting in Houston. The presentation showcases strategies for TCE development, including CD3-binding antibodies for enhanced tumor-cell killing and optimal cytokine release. The company highlighted molecules designed to improve efficacy in solid tumor treatment through T-cell activation and proliferation via CD28 and 4-1BB costimulation. The data includes preclinical characterization of TCEs targeting B7-H4 and PSMA solid tumor targets, demonstrating distinctive tumor-cell killing and cytokine release profiles compared to clinical benchmarks.
AbCellera (ABCL) reported Q3 2024 financial results with total revenue of $6.5 million, slightly down from $6.6 million in Q3 2023. The company reported a net loss of $51.1 million, or $(0.17) per share. Key operational highlights include expanding collaboration with Eli Lilly, reaching 95 partner-initiated programs (up 13% YoY), and advancing 14 molecules to the clinic (up 40% YoY). R&D expenses increased to $41.0 million, while maintaining strong liquidity of $875 million including $670.4 million in cash and equivalents, plus $205 million in available non-dilutive government funding.
AbCellera (Nasdaq: ABCL) has announced its participation in two upcoming investor conferences in November 2024. The company's executives will be presenting at:
- The Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
- The Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00 p.m. Greenwich Mean Time)
Live audio webcasts of both presentations will be accessible through links posted on AbCellera's Investor Relations website. Replays of the webcasts will also be available through the same links after the presentations conclude.
AbCellera (Nasdaq: ABCL) has announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, scheduled for November 6 to 10 at the George R. Brown Convention Center in Houston, Texas. The presentation, titled 'Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release', is assigned Abstract Number 1291 and will be displayed on Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST. Attendees can view the poster in Exhibit Halls A B of the convention center or access it online at the SITC website.
AbCellera (Nasdaq: ABCL) has announced that it will release its third quarter 2024 financial results on Monday, November 4, 2024. The company will also hold an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Investors and interested parties can access a live audio webcast of the earnings conference through a link that will be available on AbCellera's Investor Relations website. For those unable to attend the live call, a replay of the webcast will be made available through the same link following the conference call.
AbCellera (ABCL) has announced its participation in two upcoming investor conferences in September 2024. The company will present at the Wells Fargo Healthcare Conference on September 5 at 12:00 p.m. Pacific Time, and the Cantor Global Healthcare Conference on September 17 at 8:30 a.m. Pacific Time.
Investors and interested parties can access live audio webcasts of both presentations through links that will be available on AbCellera's Investor Relations website. Replays of the webcasts will also be accessible through the same links after the presentations conclude.
These conferences provide AbCellera with opportunities to showcase its latest developments and engage with the investment community, potentially impacting its stock performance and market perception.
AbCellera (Nasdaq: ABCL) announced its financial results for Q2 2024.
Revenue decreased to $7.3 million from $10.1 million in Q2 2023, with research fees contributing $5.5 million and milestone payments $1.5 million.
Expenses rose overall, with R&D expenses at $40.9 million (up from $36.5 million), G&A expenses at $20.2 million (up from $15.5 million), and S&M expenses at $3.1 million (down from $3.8 million).
Net Loss increased to $36.9 million, or $(0.13) per share, compared to $30.5 million, or $(0.11) per share, in Q2 2023.
Liquidity remains strong at $697.6 million, with $220 million in available non-dilutive funding, bringing total liquidity to over $900 million.
Key developments include clinical trial applications for ABCL635 and ABCL575 expected in Q2 2025, the initiation of three T-cell engager programs, and an expanded partnership with Lilly.
AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs. This builds on their successful partnership from March 2020, which included eight de novo programs and led to emergency use authorization for two COVID-19 antibody therapies. Under the new agreement, Lilly gains rights to develop and commercialize resulting therapeutic antibodies, while AbCellera receives an upfront payment, research payments, and potential milestone payments and royalties.
AbCellera's CEO, Carl Hansen, expressed excitement about deepening their partnership with Lilly, aiming to increase their impact on patients across multiple therapeutic areas. The expansion demonstrates the success of their initial collaboration and AbCellera's capabilities in antibody discovery and development.